10x Genomics Balances Atara Launch With Slower Growth

10X Genomics ((TXG)) has held its Q1 earnings call. Read on for the main highlights of the call.

10x Genomics’ latest earnings call struck a cautiously upbeat tone, as management balanced clear operational progress with near-term revenue headwinds. Executives highlighted strong consumables momentum, expanding margins, lower expenses, and a stronger cash position, while acknowledging a sharp drop in instrument sales and limited early production capacity for the new Atara platform.

Revenue Growth Normalized for One‑Time Items

Q1 revenue reached $150.8 million, representing 9% year‑over‑year growth once last year’s nonrecurring settlement is excluded. This framing underscores that the core business is expanding, even as headline growth looks softer when that prior legal windfall is included.

Consumables Lead with Double‑Digit Gains

Consumables remained the engine of the model, with total consumables revenue up 13% year over year. Single‑cell consumables rose 6%, driven by double‑digit reaction volume growth from FLEX and FLEX Apex, while spatial consumables surged 31% on continued Xenium momentum.

Margins Strengthen on Cost Discipline

Gross margin improved to 70% in Q1 2026 versus 68% a year earlier, supported by lower warranty costs and reduced inventory write‑downs. Management signaled that these gains reflect ongoing operational discipline rather than one‑off benefits, giving investors more confidence in margin durability.

Lower Operating Expenses and Stronger Cash

Operating expenses fell 15% year over year, or roughly 20% when excluding last year’s one‑time settlement gain. The company closed the quarter with $540 million in cash, cash equivalents, and marketable securities, up $113 million from a year ago and $16 million sequentially, bolstering its capacity to fund growth initiatives.

Atara: Flagship Spatial Platform Launch

The headline announcement was Atara, described as the company’s most significant product introduction to date for spatial whole‑transcriptome analysis. Each instrument can process up to 800 whole‑transcriptome 1 cm² samples annually, or over 3,000 with targeted Atara Select panels, and early customer response and preorders were characterized as extraordinary.

AI Partnerships and Data‑Hungry Collaborations

Management spotlighted a series of partnerships, including programs with the Chan Zuckerberg ecosystem, Arc Institute, and others, that emphasize the need for large‑scale, high‑quality biological datasets. These collaborations position 10x as a key supplier of data for AI‑driven biology, reinforcing demand for its platforms as AI models grow more sophisticated.

Product Leadership and Translational Adoption

FLEX Apex was highlighted as a game changer for large translational studies by enabling FFPE compatibility, streamlined workflows, and attractive economics for big cohorts. Xenium continues to propel spatial consumables growth and is gaining traction in translational and clinical cohort work, reinforcing 10x’s leadership in high‑end research applications.

Steady Full‑Year Outlook Maintained

The company reaffirmed its 2026 revenue outlook of $600 million to $625 million, which excluding last year’s settlement implies roughly 0% to 4% growth. This guidance explicitly embeds Atara launch dynamics and customer timing shifts, suggesting management is planning for modest near‑term expansion while investing for a larger future opportunity.

Instrument Revenue Under Pressure

Total instrument revenue declined 24% year over year in Q1, with Chromium instruments down 12% and spatial instrument revenue falling 32%. Management attributed much of this weakness to customers postponing spatial instrument purchases ahead of the Atara launch, framing the decline as cyclical rather than structural.

Atara Transition Creates Near‑Term Spatial Headwinds

Executives cautioned that spatial revenue will face temporary pressure as customers wait for Atara shipments, leading to a sequential step‑down in Q2 and a similar Q3. They also noted that Q1 represented a larger‑than‑usual share of full‑year revenue, effectively front‑loading results before the transition period.

Limited Initial Atara Capacity in 2026

Atara’s revenue contribution in 2026 will be constrained by limited initial production capacity, with only about 40 units expected to be placed between Q3 and Q4. Most of those placements are slated for Q4, meaning the bulk of Atara’s financial impact will be felt beyond the current year.

Mix and Cost Pressures on Margins

Management warned that Atara instruments will carry lower margins than the existing portfolio, creating some margin dilution and pulling full‑year gross margins into the mid‑60s. They also highlighted inflationary pressures in memory and petroleum‑based plastics as potential input cost headwinds they are actively monitoring.

Platform Migration and Cannibalization Risks

Atara’s capabilities could accelerate the migration away from older spatial platforms such as Xenium and Visium over time, putting structural pressure on those product lines. Management stated that this cannibalization dynamic has been factored into guidance, framing it as a necessary trade‑off to expand the total addressable market.

Muted Growth Outlook Despite Innovation

Despite a slate of new products and strong demand indicators, the company’s full‑year outlook implies only 0% to 4% growth when adjusted for last year’s settlement. This modest top‑line trajectory underscores a deliberate reset phase as 10x navigates the Atara rollout, instrument cycle, and customer purchasing pauses.

Forward‑Looking Guidance and Near‑Term Trajectory

Management expects revenue of $600 million to $625 million for 2026, with Q2 showing a low single‑digit sequential decline versus Q1 and Q3 tracking similarly before Atara begins to contribute more meaningfully in Q4. They reiterated expectations for double‑digit growth in single‑cell reaction volumes and spatial consumables, projected full‑year gross margins in the mid‑60s, and guided to roughly flat operating expenses year over year, supported by the $540 million cash balance.

The earnings call painted a picture of a company in strategic transition, leaning on a robust consumables franchise and disciplined cost structure while it digests a sharp instrument slowdown and phases in Atara. For investors, the near term may look subdued, but management’s message centered on building a broader, AI‑aligned platform that could support stronger growth once the current launch and capacity constraints ease.